Janssen Biotech, Pharmacyclics Explore Abbott FISH Technology as CDx for CLL | GenomeWeb

NEW YORK (GenomeWeb News) – Abbott today announced a collaboration to explore the use of its fluorescence in situ hybridization technology as a companion diagnostic for an investigational drug being developed by Johnson & Johnson's Janssen Biotech and Pharmacyclics for treating chronic lymphocytic leukemia.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.